Abstract: Objective To investigate the expressions of sodium iodide symporter （NIS） and thyroid stimulating hormone receptor （TSHR） in differentiated thyroid carcinoma （DTC） and their association with BRAF V600E mutation. Methods The immunohistochemistry SP method was used to detect the expressions of NIS and TSHR in 229 cases of DTC， 52 cases of nodular goiter and 31 cases of normal thyroid tissues. The PCR direct sequencing was applied to detect the BRAF V600E mutations. The relationship between the expressions of NIS and TSHR in DTC tissues and the clinicopathological parameters （gender， age， tumor size， lymph node metastasis， TNM stage and recurrence risk stratification） and BRAF V600E mutation were analyzed. Results The positive rate of NIS in DTC was 55.5% （127/229）， lower than 78.9% （41/52） of nodular goiter and 77.4% （24/31） of normal thyroid tissues with statistical significant difference（P<0.05）. NIS expressions were not associated with gender， age， tumor size， lymph node metastasis， TNM staging and recurrence risk stratification. The positive rates of DTC， nodular goiter and normal thyroid tissues were 41.0% （94/229）， 48.1% （25/52） and 45.2% （14/31）， and no significant difference was observed. TSHR expressions were not associated with gender， age， lymph node metastasis， TNM staging and recurrence risk stratification， but related with tumor size （P=0.029）. The positive expression rate of NIS was not related to the mutation of BRAF V600E. However， as for the NIS expression in cell cytoplasm， BRAF V600E mutation type （48.2%） was higher than BRAF V600E wild type （29.5%）. In BRAF V600E mutation type， the expression rate of NIS in cell membrane was 51.8%， lower than 70.5% of BRAF V600E wild type （P<0.05）. The positive rate of TSHR in BRAF V600E mutations type was 47.9%， higher than 28.7% of BRAF V600E wild type， and the difference was statistical significant. TSHR expression in cytoplasm/ormembrane was not associated with BRAF V600E mutations. Conclusion The NIS expression was decreased and the location of NIS expression may be associated with BRAF V600E mutations in DTC， but the location of TSHR expression was not associated with BRAF V600E mutations. The specific mechanisms of the increased TSHR expression in patients with BRAF V600E mutations need further study.